IDNA

iShares Genomics Immnlgy & Hlthcr ETF

NYSE FactSet Glb Gnmcs&Imm Bio NR USD

NAV as of 24-Nov-2023

20.4197

4 Week: 17.73 - 20.52

52 Week: 17.37 - 28.44

Latest Closing Price

20.18

Premium / Discount

-0.06

Expense Ratio

0.47%

Investment Objective

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.

Main Fund Characteristics

Fund Manager:
iShares
Asset Under Management:
120,417,958
Launch Date:
10/06/2019
Asset Class:
Equity
Replication Method:
Physical-Sample
Number of Holdings:
58
Trading Currency:
USD
Style:
Small Growth
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
NYSE

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-19.831.67-11.88
1 Day-0.930.000.00
1 Week-1.664.62-0.36
1 Month16.1811.371.42
3 Months-7.9415.32-0.52
6 Months-16.0218.81-0.85
1 Year-25.8727.09-0.95
2 Years-57.4547.26-1.22
3 Years-53.8555.62-0.97
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2013201420152016201720182019202020212022
Price (%) 0.00000.00000.00000.00000.00000.00000.000054.4943-4.0033-42.1019
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.00007.000082.000099.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
N.A

Portfolio Data

Total Number of Holdings: 58

Number of Bond Holdings: 0

Number of Equity Holdings: 44

Total Market Value: 120,417,958

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Blueprint Medicines Corp5.574798,07006,712,892
2Exelixis Inc5.3567297,53206,450,494
3Regeneron Pharmaceuticals Inc5.11667,71806,161,279

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant16.41
Large8.95
Medium9.08
Small25.29
Micro35.62

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

18.5007

Price/Book*

1.7920

Price/Sales*

2.8789

Price/Cash Flow*

12.7844

Dividend Yield*

0.5762

Growth Measures

Long-Term Earnings

7.0689

Historical Earnings

76.0522

Sales Growth

30.7483

Cash-Flow Growth

39.6063

Book-Value Growth

4.1621

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you